A Pharmacological Analysis of Delta 9-THC in Humans

Delta 9-THC 在人体中的药理学分析

• 批准号: 7071854
• 负责人: Joshua Anthony Lile
• 金额: $ 14.99万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7071854
• 关键词: GABA receptor; behavior disorders; behavior test; behavioral /social science research tag; cannabinoid receptor; cannabinoids; clinical research; cognition disorders; data collection methodology /evaluation; dopamine agonists; dopamine receptor; human subject; impulsive behavior; longitudinal human study; neurotoxicology; neurotransmitter agonist; neurotransmitter antagonist; opiate alkaloid; pharmacokinetics; psychomotor function

DESCRIPTION (provided by applicant): Dr. Lile's graduate and post-doctoral research focused on the neuropharmacological basis of stimulant addiction and how the neurotransmitter systems that mediate the effects of stimulants could be targeted for medications development. The career development and research plan proposed in this application outlines the training that will enable him to apply his previous experience, along with new methodolgies, to an emerging area of research, the treatment of cannabis-related disorders. Despite the fact that cannabis use is more prevalent than for any other illicit drug and can progress to abuse and dependence, there are no pharmacotherapies for these disorders and little clinical research has been conducted to this end. The experiments described here were designed to identify the neurotransmitter systems that are involved in the effects of the primary active constituent of cannabis, delta 9-THC, in humans. The primary outcome variable for these experiments is the interoceptive cue produced by delta 9-THC. The interoceptive effects of delta 9- THC will be measured using the drug-discrimination procedure, which is a pharmacologically specific and sensitive means to characterize the profile of a drug. Because cannabis-related disorders are associated with maladaptive changes in behavior and cognition, additional experimental measures to assess reinforcement, subjective ratings, impulsivity, psychomotor performance, learning and memory will also be taken. The role of the cannabinoid, opioid, GABA and dopamine systems will be investigated, which will reveal targets for future research efforts. Dr. Lile will be sponsored by Dr. Kelly, an expert in cannabis research in humans. The conduct of these experiments and the training described in this proposal will occur at the University of Kentucky, which has an extensive community of scientists engaged in basic and clinical research related to drug addiction. This award will allow Dr. Lile to develop as an independent investigator and to establish a program of human research concentrated on cannabis-related disorders.

描述（由申请人提供）： Lile博士的研究生和博士后研究的重点是兴奋剂成瘾的神经药理基础，以及如何将介导兴奋剂作用的神经递质系统用于药物开发。本申请中提出的职业发展和研究计划概述了培训，这将使他能够将自己以前的经验以及新的方法应用于新兴的研究领域，即与大麻相关疾病的治疗。尽管大麻使用比其他任何非法药物都更为普遍，并且可以发展为滥用和依赖，但这些疾病没有药物治疗，而且几乎没有进行临床研究。此处描述的实验旨在识别与人类在人类中主要活性成分的主要活性组成部分有关的神经递质系统。这些实验的主要结果变量是Delta 9-THC产生的感受性提示。 Delta 9-THC的互感作用将使用药物歧视程序进行测量，这是一种在药理特异性和敏感的手段，以表征药物的特征。由于与大麻相关的疾病与行为和认知的适应不良变化有关，因此还将采取其他实验措施，以评估强化，主观评分，冲动性，精神运动表现，学习和记忆。将研究大麻素，阿片类药物，GABA和多巴胺系统的作用，这将揭示未来研究工作的目标。 Lile博士将由人类大麻研究专家Kelly博士赞助。这些实验的行为和本提案中描述的培训将在肯塔基大学进行，肯塔基大学拥有广泛的科学家社区，从事与药物成瘾有关的基础和临床研究。该奖项将使Lile博士能够发展为独立研究者，并建立一个集中于与大麻相关疾病的人类研究计划。